Search In this Thesis
   Search In this Thesis  
العنوان
Ultrasonographic Scoring System Score Versus Liver Stiffness Measurement Compared to Histopathological Findings in Diagnosis of Cirrhosis in HCV Infected Egyptian Patients/
المؤلف
Elsharkawy ,Ehab Mahmoud .
هيئة الاعداد
باحث / إيهاب محمود الشرقاوى
مشرف / خالد محمد حسين عبد الوهاب
مشرف / عصام محمد بيومى هلال
مشرف / أمير حلمى سامى
مشرف / أحمد السعدى محمد خيال
مشرف / أحمد إبراهيم الشافعى
تاريخ النشر
2017.
عدد الصفحات
118.p;
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
الطب الباطني
تاريخ الإجازة
1/1/2017
مكان الإجازة
جامعة عين شمس - كلية الطب - Internal Medicine
الفهرس
Only 14 pages are availabe for public view

from 112

from 112

Abstract

Chronic hepatitis C infection represents a major cause of liver related morbidity and mortality. Egypt ranked number 1 worldwide in the prevalence of chronic hepatitis C. But great efforts are going on to improve diagnosis and treatment of those patients.
Noninvasive methods for detection of liver fibrosis and cirrhosis in the CHC patients are helpful for diagnosis and follow up of those patients.
This study was conducted on 60 Egyptian patients with CHC in the period between September 2014 and February 2016. Our studied patients were recruited from Ain Shams University Hospitals during their preparation for antiviral treatment. We tested the diagnostic value of Ultrasound Scoring System Score (USSS) compared to liver stiffness measurement by Transient Elastography in diagnosis of liver fibrosis and cirrhosis in our studied patients. Histological examination of liver biopsy was the standard of care till that time to compare with in all patients in addition to other laboratory parameters including CBC, liver function tests, viral load by quantitative PCR.
However the small number of patients is a considerable limitation of this study. The use of TE or USSS as non invasive method is advised in further large scale studies in chronic HCV patients and in other categories of liver diseases.
We concluded from this study that all patients with chronic HCV infection should be considered for anti viral treatment, irrespective of severity of liver fibrosis; Since cure is possible with the new highly effective DAAs.
With this paradigm shift in the management of chronic HCV patients, The role of invasive markers for fibrosis become diminished or changed. However , the considerable cost of these treatments has necessitated prioritization for chronic HCV patients based on fibrosis severity.